Clinical Trial Update: Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the DPP-4 inhibitor omarigliptin (MK-3102) in obese participants and in participants with Type 2 Diabetes; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Omarigliptin (omarigliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes (T2D) | Phase 1 | Status: COMPLETED | Results posted: 2015-12-24